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ABSTRACT 
Conventional electrophysiologic measurements parameters of diabetic sural nerves and 
such as nerve conduction velocity, compound electrophysiologic and sensory score measurements 
action potential, and neuropathic symptom scores of the same sural nerve. These data suggest that 
have been used to assess the severity of diabetic detailed morphometric examination is a more 
neuropathy and have been the major efficacy end sensitive and reproducible method for assessing 
points following pharmacologic intervention trials. the severity of diabetic neuropathy, and that 
Unfortunately, these measurements are not quantitative morphometric parameters provide 
particularly sensitive and their reproducibility is, sensitive indicators of electrophysiologic and 
at best, good. Detailed morphometric analysis of clinically meaningful nerve damage. Morphometric 
sural nerve biopsies has evolved as a sensitive and analysis of sural nerve biopsies therefore 
highly reproducible method for assessing the constitutes a rational basis for sensitive efficacy 
severity and progression of diabetic peripheral end points in the design of future therapeutic 
neuropathy. In this study we demonstrate highly clinical trials. (Journal of Diabetes and Its 
significant correlations between morphometric Complications 6;1:64-68, 1992.) 
INTRODUCTION nerve biopsy has been utilized as a research tool to 
A number of methods are available for evaluating dia- 
evaluate structural changes taking place in diabetic 
betic neuropathy; however, each is associated with 
neuropathic tissue. * Morphometric analysis of sural 
some limitation. Electrophysiologic parameters such 
nerve biopsies has developed as a sensitive and repro- 
as nerve conduction velocity and clinical assessments 
ducible technique for determining the severity and 
such as neuropathic symptom scores are valuable for 
progression of diabetic neuropathy. On the other 
the clinical assessment of diabetic polyneuropathy. 
hand, widespread use of nerve biopsy is not practical 
Unfortunately, these techniques are not reliable indi- 
for assessing clinical responses in large populations 
caters of the severity of diabetic polyneuropathy, nor 
of patients. Nevertheless, if the results from morpho- 
are they highly reproducible. In recent years, sural 
metric analysis of disease activity could be correlated 
with electrophysiologic and clinical parameters, then 
morphometric parameters might be used to evaluate 
therapeutic responses in clinical trials. 
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recently in clinical diabetic neuropathy research. First, 
Michigan Diabetes Research and Training Center, University of the correlation between various structural abnormali- 
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and electrophysiologic parameters will be examined. 
Second, the correlation between specific structural ab- 
normalities and sensory scores taken from the same 
sural nerves will be discussed. 
CORRELATION BETWEEN STRUCTURAL AND 
ELECTROPHYSIOLOGIC ABNORMALITIES IN 
DIABETIC NEUROPATHY 
In clinically overt diabetic neuropathy there is a loss 
of functional units such as myelinated nerve fibers. 
Moreover, preserved fibers in the diabetic nerve are 
smaller in size, as compared with age-matched con- 
trols. In addition, specific structural lesions occur at 
various sites in these functional units, particularly at 
sites that are of major functional importance. Lesions 
that occur in the chronic diabetic nerve consist of 
nerve fiber loss, atrophy, and specific fiber lesions, 
and may be termed the “triopathy of diabetic neu- 
ropathy.” 
The nerve fiber population of peripheral nerve con- 
stitutes the structural substrate for nerve function. In 
the myelinated nerve fiber the electrical impulse is 
generated at the node of Ranvier and propagated 
along the internodal axon. Hence, the maintenance of 
normal nerve conduction velocity is dependent on the 
functional and structural integrity of the node of Ran- 
vier and the internodal segment. 
The characteristic structural abnormalities occur- 
ring in diabetic nerve affect the node of Ranvier and 
the internodal axon. These progressive, structural le- 
sions are therefore likely candidates for causing the 
impaired function of the chronically diabetic nerve. 
The node of Ranvier of myelinated fibers is the site 
of a sequence of structurally well defined changes, 
both in murine and human diabetic neuropathy. 
These changes are initiated by nodal and paranodal 
swelling, and abnormality which has been extensively 
studied in the diabetic Bio-breeding Wistar (BB/W) rat 
and subsequently identified in the streptozotocin dia- 
betic rat. In human diabetic subjects, nodal swelling 
appears to be a consequence of intra-axonal sodium 
accumulation.’ Nodal swelling is followed by the pro- 
gressive loss of axo-glial junctions, leading to detach- 
ment of the terminal myelin loops from the paranodal 
axolemma, which in turn results in paranodal demye- 
lination and widening of the nodal gap. Paranodal 
demyelination is repaired by the formation of new 
myelin, resulting in intercalated, thinly myelinated 
nodes. 
We previously discussed the electrical events which 
occur at the node of Ranvier and how these events 
relate to various structural lesions.3,4 In a normal situ- 
ation, the terminal myelin loops are anchored to the 
axolemma by so-called axo-glial junctions (Figure 1). 
The axo-glial junctions form a barrier system, prevent- 
ing lateral migrations of the nodal sodium channels 
FIGURE 1 Schematic illustration of the nodal changes occurring 
in diabetes (right) compared to the normal situation &ft~. Note 
loss of axo-glial junctions (red original figure) in the diabetic nerve 
permitting migration of sodium channels (yellow original figure) 
from the nodal axolemma into the internode (arrows). 
away from the nodal axolemma. One of the character- 
istic lesions that is seen in the BB/W and streptozo- 
tocin diabetic rats and in human diabetic neuropathy 
is a progressive loss of these junctional complexes.’ 
The progressive loss of axo-glial junctions allows for 
the migration of sodium channels into the internodal 
axolemma. The diminution of the density of sodium 
channels at the node of Ranvier correlates with a de- 
crease in sodium permeability that has been demon- 
strated experimentally, and is associated with a delay 
in the generation of the electrical impulse at the node 
of Ranvier. 
With respect to internodal abnormalities, we and 
others have demonstrated axonal atrophy as being a 
characteristic lesion in both experimental and human 
diabetic neuropathy. Axonal atrophy is followed by 
axonal degeneration and Wallerian degeneration, 
leading to a net loss of functional nerve units in the 
diabetic nerve. The fiber atrophy that is observed is 
caused mainly by atrophy of the axon, associated with 
a corrugated and wrinkled appearance of the sur- 
rounding myelin sheath, which is relatively unaf- 
fected by the disease (Figure 2). 
These axonal abnormalities can be quantified in de- 
tail. One method of quantifying axonal atrophy is the 
measurement of the axon/myelin ratio. The axon/my- 
elin ratio is obtained by measuring the cross-sectional 
area of the axon and dividing it by the thickness of 
the myelin sheath, expressed as the number of myelin 
lamella. Axonal atrophy can be assessed in other 
ways. In single test fiber preparations the frequency 
of myelinated fibers exhibiting excessive myelin wrin- 
kling provides a good estimate of the extent of axonal 
atrophy. Axonal atrophy can also be assessed by cor- 
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FIGURE 2 Electron micrograph of a myelinated fiber in a dia- 
betic nerue demonstrating axonal atrophy and abnormal wrinkling 
of the myelin sheath. 
relating the internodal length with the diameter of the 
fiber. Under normal circumstances, there is a linear 
relationship between the internodal length and the 
diameter of the same fiber. 
The specific structural changes that occur at the 
node of Ranvier can be accurately quantified. For in- 
stance, axo-glial dysjunction is expressed as the num- 
ber of myelin loops without junctions and is ex- 
pressed as a percentage of the total number of myelin 
loops. When axo-glial dysjunction and nerve conduc- 
tion velocity are examined in experimental diabetes in 
the BBMr rat, a highly significant correlation is ob- 
served, regardless of whether the rats are normal con- 
trols, untreated diabetic rates, or treated with insulin 
or an aldose reductase inhibitor.5 This suggests that 
there is a direct correlation between this structural 
abnormality, axo-glial dysjunction, and the function, 
nerve conduction velocity. 
These findings formed the basis for examinations 
of correlations between specific structural lesions in 
human diabetic nerve and nerve conduction velocity 
of the same nerve. These data were acquired from 
various clinical trials in which patients had been 
treated either with an aldose reductase inhibitor or a 
placebo. 
Two abnormalities were examined: axo-glial dys- 
jixnction and axonal atrophy, which, from a theoreti- 
cal viewpoint, may impact upon the propagation of 
the electrical impulse. These measurements were cor- 
related with measurements of nerve conduction ve- 
locity obtained from the same sural nerves prior to 
biopsy. Highly significant correlations were observed 
between conduction velocity and the product of axo- 
glial dysjunction and axonal atrophy, whether the lat- 
ter was measured by axon/myelin ratio, by internodal 
diameter ratio, or by excessive wrinkling of myelin- 
ated fibers. Hence, similar to the findings in the rat 
model, structural abnormalities that occur in human 
diabetic neuropathy appear to be major determinants 
for the slowing of nerve conduction velocity in clini- 
cally overt diabetic neuropathy. 
In a clinical trial with the aldose reductase inhibitor, 
sorbinil, sural nerve biopsies were obtained at the out- 
set of the trial and following its completion.’ Sural 
nerve conduction velocities were obtained at the same 
time points. A small but significant increase in the 
sural nerve conduction velocity was observed in sorb- 
inil-treated patients compared with placebo-treated 
patients. This was accompanied by structural im- 
provements of axo-glial dysjunction. When axon/ 
myelin ratio was assessed, a significant improvement 
following sorbinil treatment was observed suggesting 
that repair of axonal atrophy occurred following treat- 
ment with sorbinil. Similarly, when internodal length/ 
diameter ratio or the frequency of excessively wrin- 
kled fibers were examined, highly significant im- 
provements occurred following sorbinil treatment. If 
the changes from baseline to follow-up with respect 
to axo-glial dysjunction and axonal atrophy were ex- 
amined and compared with the change in nerve con- 
duction velocity, highly significant correlations be- 
tween the improvements in structural parameters and 
nerve conduction velocity were demonstrated, re- 
gardless of whether axonal atrophy was assessed by 
axon/myelin ratio, internodal length diameter, or by 
excessive myelin wrinkling (Table 1). 
A simple and straightforward morphometric pa- 
rameter for the assessment of severity of neuropathy 
is the myelinated fiber density. Myelinated fiber den- 
sity decreases progressively with the progression of 
TABLE 1. CORRELATION BETWEEN NERVE 
CONDUCTION VELOCITY AND MORPHOMETRIC 
PARAMETERS 
Parameter r Value p Value 
Nerve Conduction Velocity 
AGD x M/A 
AGD x IL/D 
AGD x MW 
A Nerve Conduction Velocity 
AAGD x AM/A 
AAGD x AIL/D 
AAGD x AMW 
-0.73 <0.0001 





AGD, axo-glial dysjunction; MIA, myelinlaxon ratio; ILID, internodal 
length/fiber diameter; MW, myelin wrinkling; A, change. 
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the disease. We have previously shown that the am- 
plitude of the evoked compound sensory response 
in diabetic nerves correlates with fiber density in the 
sorbinil trial. ’ 
In another aldose reductase trial of tolrestat, con- 
ducted in patients with more severe diabetic neuropa- 
thy, an almost identical correlation between sural 
nerve amplitude and myelinated fiber density was 
demonstrated, suggesting that this is a valid struc- 
ture/function correlation. 
To summarize these initial findings, it can be said 
that 
1. Sural nerve conduction velocity correlates with 
axo-glial dysjunction and axonal atrophy in the 
sural nerve. 
2. Improvement in sural nerve conduction velocity 
following aldose reductase inhibitor treatment cor- 
relates with the improvement in axo-glial dysjunc- 
tion and axonal atrophy. 
3. Sural nerve compound action potential amplitude 
correlates well with myelinated fiber density. 
CORRELATION BETWEEN STRUCTURAL 
ABNORMALITIES AND CLINICAL 
ASSESSMENTS 
We have attempted to correlate the structural abnor- 
malities occurring in sural nerve with the sensory 
score in patients with diabetic neuropathy. Myelin- 
ated fiber density abnormalities account for more than 
20% of the defect that is seen in the sensory score. A 
subgroup of patients with diabetic neuropathy from 
two trials of aldose reductase inhibitors underwent 
sural nerve biopsy and were available for comparison. 
The two studies were the Sorbinil North American 
trial conducted in 28 patients, and the Tolrestat 
United States study in which 27 patients were stud- 
ied. Sensory score was ascertained from the clinical 
neurologic examination. Touch, pinprick, vibration, 
position, and temperature sense were scored as either 
normal (0), reduced (l), or absent (2), and the sum of 
that score was used for comparison with the morpho- 
metric parameters. 
In the sorbinil trial, there was a good correlation 
( r2 = 0.234) between myelinated fiber density and the 
sensory score (Figure 3). Similarly, data obtained at 
the termination of the tolrestat trial also revealed a 
high correlation (y2 = 0.44) (Figure 4). Furthermore, 
we correlated the same clinical parameters with a 
structural index of normality. The index of normality 
was defined as fiber density times the percentage of 
normal fibers assessed from teased fiber preparations. 
This morphometric index provides the density of 
structurally normal fibers in the nerve. Although the 
correlation was less than with density alone, signifi- 
cant correlations were observed between the sensory 
R-squared = 0.234 
0 
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FIGURE 3 Correlation between senso y score and fiber density 
at the outset of the Sorbinil North American trial. 
score and the index of normality in both of these trials. 
Therefore, correlations appear to exist between struc- 
tural abnormalities and deficits obtained from a clini- 
cal neurologic examination such as the sensory score. 
What is the significance of this information? Dr. Son- 
ksen in the United Kingdom has performed power 
calculations of different end points to determine the 
number of patients required to demonstrate efficacy 
in a clinical trial, such as those referred to above 
(Table 2). If vibration threshold is used as the primary 
end point, the large coefficient of variation of this 
measure requires that an enormous number of pa- 
tients be enrolled in a single trial to demonstrate sig- 
nificant improvements. If electrophysiologic param- 
eters are used as primary end points, the situation is 
somewhat better. With motor nerve amplitude as the 
efficacy end point, approximately 175 patients are 
needed to demonstrate efficacy. With respect to the 
number of patients required to show a significant im- 
provement, the best electrophysiologic parameter is 
nerve conduction velocity; less than 50 patients are 
needed in a clinical trial to show significant im- 
provement. 




FIGURE 4 Correlation between senso y score and fiber density 
at the termination of the Tolrestat United States trial. 
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TABLE 2. ANALYSIS OF THE NUMBER OF PATIENTS REQUIRED TO DETECT A SIGNIFICANT DIFFERENCE 
FOR DIFFERENT END POINTS 
Parameter 
Detectable Change for 
55 Patients/Group; 90% 
Power; 5% Significance 
Dyck and O’Brien 
(1988) No. of Patients/Group 
Median MNCV (m/set) 2.2 2.5 42 
Median MNA (mV) 2.25 1.2 175 
Great toe VT (volts) 6.4 1.4 >550 
MNCV, motor nerve conduction velocity; MNA, motor nerve amplitude; VT, vibration threshold. 
In contrast, if more precise morphometric assess- 
ment techniques are used to show significant im- 
provement in nerve morphology, less than one-half 
the number of patients are required. Morphometric 
analyses of nerve tissue can therefore be used as sen- 
sitive efficacy end points and can be extrapolated to 
less precise measurements, such as electrophysiologic 
parameters and the sensory exam. 
CONCLUSIONS 
The present data suggest that in peripheral nerve spe- 
cific structural, quantifiable lesions correlate closely 
with electrophysiologic parameters such as nerve con- 
duction velocity and the amplitude of evoked re- 
sponse. Furthermore, the detailed morphometric as- 
sessment of nerve structure correlates surprisingly 
well with the quantified clinical exam. Due to the 
specificity and reproducibility of morphometric analy- 
sis, it can be used advantageously in sensitive efficacy 
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